Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02759185 · ClinicalTrials.gov registry record · Phase 2

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

A Phase 2 study of Posttraumatic Stress Disorder, sponsored by Multidisciplinary Association for Psychedelic Studies.

Completed
Registry status
Phase 2
Development phase
80
Enrollment target
1
Study location

NCT02759185 is a Phase 2 study of Posttraumatic Stress Disorder that has completed, run by Multidisciplinary Association for Psychedelic Studies. The registered enrollment target is 80 participants, below the 111-participant average among 117 other Posttraumatic Stress Disorder trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02759185, a Phase 2 study of Posttraumatic Stress Disorder, has completed, sponsored by Multidisciplinary Association for Psychedelic Studies.

COMPLETED
Registry status
Phase 2
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

This pilot study gathered preliminary evidence of the safety and efficacy of four potencies of smoked cannabis to manage chronic, treatment-resistant PTSD among veterans: (1) High THC/ Low CBD (High THC), (2) Low THC/High CBD (High CBD), (3) High THC/ High CBD (THC/CBD) and (4) Low THC/Low CBD (placebo). The study will produce preliminary evidence to help elucidate the potential effects of THC, CBD, or a combination of both constituents to reduce PTSD symptoms. Smoked cannabis will be tested in two stages of three weeks each (Stage 1 and Stage 2), with a two-week cessation period after each stage, verified by blood/urine cannabinoid analysis. The primary objective was to compare three active concentrations of smoked cannabis and placebo on PTSD symptom severity measured by CAPS-5 total severity scores during Stage 1.

Conditions Studied

Posttraumatic Stress Disorder

Interventions

  • DRUG High THC cannabis
  • DRUG High CBD cannabis
  • DRUG THC/CBD cannabis
  • DRUG Placebo cannabis

Study Locations (1)

Arizona

  • Scottsdale Research Institute - Phoenix

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2017-01-02
Est. Completion 2019-01
Phase Phase 2

Sponsor

Multidisciplinary Association for Psychedelic Studies

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02759185

The ClinicalTrials.gov registry entry for NCT02759185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 111-participant average among 117 other Posttraumatic Stress Disorder trials with a reported enrollment target (28% lower). The listed sponsor is Multidisciplinary Association for Psychedelic Studies, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Posttraumatic Stress Disorder appearing as the primary indexed condition, and to 4 interventions - of which High THC cannabis is the first listed.

NCT02759185 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT02759185 about?

NCT02759185 is a clinical study titled "Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD". This pilot study gathered preliminary evidence of the safety and efficacy of four potencies of smoked cannabis to manage chronic, treatment-resistant PTSD among veterans: (1) High THC/ Low CBD (High THC), (2) Low THC/High CBD (High CBD), (3) High THC/ High CBD (THC/CBD) and (4) Low THC/Low CBD (plac...

What is the current status of trial NCT02759185?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2017-01-02. Estimated completion is 2019-01.

What conditions does trial NCT02759185 study?

This clinical trial studies the following conditions: Posttraumatic Stress Disorder.

What interventions are being tested in trial NCT02759185?

The interventions under investigation include: High THC cannabis (DRUG), High CBD cannabis (DRUG), THC/CBD cannabis (DRUG), Placebo cannabis (DRUG).

Who is sponsoring clinical trial NCT02759185?

This trial is sponsored by Multidisciplinary Association for Psychedelic Studies, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02759185 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Posttraumatic Stress Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Posttraumatic Stress Disorder

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.